



## Crescent Biopharma to Present at March Investor Conferences

February 23, 2026

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- [Crescent Biopharma, Inc.](#) ("Crescent" or the "Company") (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in March:

- **TD Cowen 46<sup>th</sup> Annual Health Care Conference**, fireside chat on Monday, March 2, 2026 at 3:50 p.m. ET in Boston.
- **Leerink Partners 2026 Global Healthcare Conference**, fireside chat on Wednesday, March 11, 2026 at 8:40 a.m. ET in Miami.

A live webcast of each presentation will be available in the Investors section of Crescent's website at <https://investors.crescentbiopharma.com/events-presentations>, and a replay will be accessible for 90 days.

### About Crescent Biopharma

Crescent Biopharma's vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company's clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit [www.crescentbiopharma.com](http://www.crescentbiopharma.com) and follow the Company on [LinkedIn](#) and [X](#).

### Contact

Amy Reilly  
Chief Communications Officer  
[amy.reilly@crescentbiopharma.com](mailto:amy.reilly@crescentbiopharma.com)  
617-465-0586